Erlonat 150 mg Tablets

Erlonat 150 mg Tablets Specification

Indication
Non-Small Cell Lung Cancer (NSCLC) & Pancreatic Cancer

Salt Composition
Erlotinib Hydrochloride 150 mg

Dosage Form
Tablets

Feature
Oral targeted therapy

Ingredients
Erlotinib Hydrochloride and Excipients

Application
Cancer Treatment

Physical Color/Texture
White to off-white, film-coated tablets

Fermentation Smell
Odorless

Storage Instructions
Store below 30C, protect from light and moisture.

Shelf Life
24 months from date of manufacture

Warning
To be used under supervision of qualified oncologist

Trade Name
Erlonat 150 mg

Tablet Shape
Round

Packaging Size
30 Tablets per box

Route of Administration
Oral

Strength
150 mg per tablet

Patient Population
Adults only

Marketed By
Natco Pharma Ltd.

Prescription Status
Prescription Only Medicine

Inactive Ingredients
Lactose monohydrate, sodium starch glycolate, microcrystalline cellulose, magnesium stearate, etc.

Regulatory Approval
Approved by regulatory authorities as per Indian norms

ATC Code
L01XE03

About Erlonat 150 mg Tablets

Erlonat (erlotinib) is principally used to treat cell lung malignancy, or pancreatic growth when joined with a specific other prescription. It works by restraining development to nearby tissues in the body with the goal that the malignant cells back off, permitting the patient a superior domain to recuperate and battle the tumor normally.

Dosages and administration :

Regularly, a grown-up patient will be told to take in the vicinity of 100mg and 150mg of erlonat (erlotinib), no less than 1 hour before any suppers or tidbits and 2 hours after. Unless generally trained, you ought to dependably gulp down every tablet without biting, squashing, part, or dissolving the tablet in fluid. Wash tablets down with full glass of water.
Reactions are coughing, fever, weakness, chest torments, severe or constant nausea, vomiting, diarrhea, eye discomfort, irritated or dry skin, inward developing eyelashes, unusual wounding or bleeding, loss of craving
Packaging: 150 mg tablet 30 tablets
Erlonat tablets - erlotinib 100mg (natco pharma)

Erlonat contains erlotinib and has a place with a class of prescriptions called kinase inhibitors.

Utilized for :

Erlonat is utilized for the treatment of non-little cell lung tumor. Erlonat is utilized as a part of blend with gemcitabine for the treatment of pancreatic growth that has spread to adjacent tissues or to different parts of the body.

Produced By : NATCO

Product Name :	Erlonat
Contains :	Erlotinib hydrochloride
Form :	Tablet
Strength :	100 mg & 150 mg
Packing :	Pack Of 30 Tabs

Targeted Cancer Therapy

Erlonat 150 mg Tablets offer a precision approach to treating non-small cell lung cancer and pancreatic cancer. Working by inhibiting abnormal growth signals in cancer cells, it is formulated for those seeking advanced, evidence-based treatment as recommended by oncologists. Its utility extends to adults only, ensuring focused action and monitored safety.

Patient Safety and Usage Protocol

Given its potent effects and prescription-only status, Erlonat 150 mg must be taken strictly as directed by a qualified oncologist. Patients should adhere to the recommended oral dosage regimen, typically one tablet per day, unless otherwise instructed. Close monitoring is essential to maximize benefits and minimize side effects throughout the treatment course.

Storage and Handling Guidelines

To maintain effectiveness, Erlonat 150 mg Tablets should be stored at temperatures below 30C, shielded from light and moisture. Each box contains 30 tablets marked E150 for easy identification. These guidelines help ensure stability and safety throughout the products 24-month shelf life.

FAQs of Erlonat 150 mg Tablets:

Q: How should Erlonat 150 mg Tablets be taken?

A: Erlonat 150 mg Tablets should be taken orally, usually once daily, as directed by your oncologist. Swallow the tablet whole with water, and follow any specific instructions provided for meals or timing.

Q: What cancers are treated with Erlonat 150 mg Tablets?

A: This medication is indicated for adults with non-small cell lung cancer (NSCLC) and pancreatic cancer, making it suitable for targeted therapy in these specific cancers as prescribed by your oncologist.

Q: When should Erlonat 150 mg not be used?

A: Erlonat 150 mg should not be used without a prescription or supervision by a qualified oncologist. It is not intended for use in children or individuals with known hypersensitivity to erlotinib or any of the excipients.

Q: Where can I purchase Erlonat 150 mg Tablets?

A: You can obtain Erlonat 150 mg Tablets from authorized dealers, distributors, exporters, suppliers, or wholesalers in India. A valid prescription from a healthcare provider is mandatory for purchase.

Q: What benefits does Erlonat 150 mg offer to cancer patients?

A: As an oral targeted therapy, Erlonat 150 mg disrupts cancer cell growth signals, potentially slowing disease progression and improving prognosis in adults with NSCLC or pancreatic cancer under medical supervision.

Q: How should Erlonat 150 mg Tablets be stored?

A: Store Erlonat 150 mg Tablets below 30C, away from light and moisture, in their original packaging. Always keep them out of reach of children and only use within the 24-month shelf life.

Q: What should be expected during the treatment process?

A: Regular monitoring by your oncologist is expected to assess response and manage potential side effects. Maintaining open communication and adhering to prescribed dosages is crucial for safety and efficacy.

Get Latest Price